Weight loss built for your health

Alyveᴿˣ has been involved in the weight loss and peptide industry for years and are the creators of the PermeAct™ Delivery Technology. They identified a major gap in the market — many patients who could benefit from life-changing medications were held back by a fear of needles, leaving them without access to effective treatment. Alyveᴿˣ solved this problem by developing sublingual and transdermal delivery methods, making these medications accessible to everyone.

No, you don’t need insurance to make treatment accessible! Our care model is designed to make access straightforward and affordable without requiring coverage.

Our network of partner physicians may prescribe FDA-approved and compounded medications. Other offerings may include peptide therapies and medications that support metabolism, recovery, or performance; based on clinical suitability and your health goals.
Note: Compounded medications are prepared based on specific patient needs and are not reviewed or approved by the FDA for safety or effectiveness. Prescription required. Results may vary.

PermeAct™ delivery technology is different from other delivery technologies in several ways.
It has been clinically researched and validated in several different formats and also been featured in various clinical studies in finished formulations that have resulted in publications in scientific journals.
The delivery technology is capable of use in both topical and oral products and consist of all GRAS ingredients making it safe for use in any format.
To date, we have not found any compound of any particle size that we cannot deliver through physiological tissue to create a positive effect both locally and systemically.
The PermeAct™ technology does not affect the compound or carrier vehicle. Instead, it reacts with surface tissue that allows for both sublingual and transdermal permeation.

PermeAct™ Delivery Tech also know as ALM Delivery Technology is a unique and proprietary delivery technology shown to enhance active ingredient uptake and bioavailability, regardless of particle size.
Produced using a highly specific and proprietary process, it not only helps amplify the absorption and bio-availability of ingredients, but also provides a direct benefit to cellular physiology.
Effects can be made more or less assertive as desired (to keep active compounds local or create a more systemic effect).

The self-contained delivery system creates a phenomenon akin to electroporation, in which electrostatic repulsion creates short-lived electric voltage pulses. This opens ionic channels on physiologic tissue allowing delivery of constituents, either topically of orally.

PermeAct™ Delivery Tech has been evaluated in human skin tissue cultures, animal testing (non-cruel), and human studies including double-blind placebo-controlled studies. The technology has been demonstrated to be capable of creating physiological responses with compounds that would normally be unable to penetrate tissue membranes, creating both profound local and/or definitive systemic benefits.

A number of articles have appeared in peer reviewed journals featuring proprietary formulations combined with differing iterations of the PermeAct™ Delivery Tech. Some of the better-known publications include The Journal of The Royal Society of Chemistry, The Journal of FASEB (Federation of American Societies of Experimental Biology), The American Journal of Clinical Nutrition, The Journal of Addiction Research & Therapy, and The American Journal of Biomedical Science & Research.